Skip to content
Screener

Edgewise Therapeutics, Inc. EWTX Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
$4.11M+77.9%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$1.37M+180%
Scholar Rock logo
Scholar RockSRRK
$136K-90.2%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1M-50.0%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
$1.22M-20.1%

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$4.73B+254%
Enterprise value$4.7B+262%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0.0×
Current ratio22.6×+1.6×

Where this comes from

Reported directly by Edgewise Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 8:09 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056713
Line itemThree months ended March 31, 2026Three months ended March 31, 2025
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation537513
Stock-based compensation8,7159,059
Accretion of discount on marketable securities, net(1,013)(1,923)
Amortization of right-of-use asset5341
Changes in assets and liabilities:
Prepaid expenses and other assets3,045(1,478)
Accounts payable1,4462,858

Item 1. Financial Statements (Unaudited)

FAQ

What is Edgewise Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
Edgewise Therapeutics, Inc. (EWTX) reported accretion (amortization) of discounts and premiums, investments of $1.01M in Q1 2026.
How has Edgewise Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
Edgewise Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 47.3% year-over-year, from $1.92M to $1.01M.
What is the long-term trend for Edgewise Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
Over 3 years (2022 to 2025), Edgewise Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a 141.7% compound annual growth rate (CAGR), from $543K to $7.67M.
What does accretion (amortization) of discounts and premiums, investments mean?
This metric represents the non-cash adjustments to the carrying value of investment securities resulting from the amortization of premiums or the accretion of discounts. It reflects the systematic allocation of the difference between the purchase price and the face value of debt securities over their remaining term. Investors use this to understand the non-cash impact of investment portfolio accounting on reported operating cash flows.

Ask your AI about Edgewise Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude